Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Health Care Conference

  Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2013
  Health Care Conference

Business Wire

CAMBRIDGE, Mass. -- May 7, 2013

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update
at the Bank of America Merrill Lynch 2013 Health Care Conference on Tuesday,
May 14, 2013 at 5:00 p.m. Pacific Time / 8:00 p.m. Eastern Time at the Encore
at the Wynn in Las Vegas.

A live webcast of Ironwood’s presentation will be accessible through the
Investors section of the company’s website at To
access the webcast, please log on to the Ironwood website approximately 15
minutes prior to the start time to ensure adequate time for any software
downloads that may be required. A replay of the webcast will be available on
Ironwood’s website for 14 days following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is committed to the art and science of
making medicines, from discovery through commercialization. We’re focused on
three goals: transforming knowledge into medicines that make a difference for
patients, creating value that will inspire the continued support of our fellow
shareholders, and building a team that passionately pursues excellence. Our
first product, linaclotide, is approved in the United States and Europe. Our
pipeline priorities include exploring further opportunities for linaclotide,
leveraging our deep expertise in functional gastrointestinal disorders, and
advancing programs in other areas such as allergic conditions, cardiovascular
disease, central nervous system disorders and other conditions defined by
patient symptoms. Ironwood was founded in 1998 and is headquartered in
Cambridge, Mass. Connect with us at or on Twitter at to learn more about Ironwood. Information that
may be important to investors will be routinely posted in both these


Ironwood Pharmaceuticals, Inc.
Media Relations
Lisa Buffington, 617-374-5103
Vice President, Corporate Communications
Investor Relations
Meredith Kaya, 617-374-5082
Associate Director, Investor Relations
Sponsored Links
Sponsored Links